Complex All-comers and Patients With Diabetes or Prediabetes Treated With Xience Sierra Everolimus-eluting Stents

  • STATUS
    Recruiting
  • participants needed
    1757
  • sponsor
    Foundation of Cardiovascular Research and Education Enschede
Updated on 16 February 2024
clinical syndrome
stenosis
everolimus
myocardial infarction
infarct
acute coronary syndrome
percutaneous coronary intervention
unstable angina
angina pectoris
coronary artery stenosis
glucose intolerance
clinical syndromes
prediabetes
diabetes

Summary

Drug eluting stents (DES) are widely used for treatment of coronary artery lesions. The Xience Sierra stent has a refined design of the metal stent backbone and is used in patients with various clinical syndromes and in different lesions. Clinical outcome of patients with previously unknown (silent) diabetes and prediabetes is of increasing interest since the latter group has recently shown to be associated with a significant risk of adverse cardiovascular events after treatment with contemporary DES. Outcome data in a population of high-risk all-comer patients, including many patients with diabetes mellitus and prediabetes, would be of great interest, but such data are not available yet. In addition, there is a lack of data in a general all-comer population. Therefore, the COASTLINE study will primarily assess the safety and efficacy of the Xience Sierra stent in a general all-comer population as well as a high-risk all-comer population.

Details
Condition Coronary Restenosis, Chest Pain, Chest Pain, Coronary Artery Disease, Coronary Artery Disease, Coronary heart disease, Myocardial Infarction, Acute Coronary Syndrome, Coronary Artery Stenosis, Angina Pectoris, Unstable angina, Ischemic Heart Disease
Age 18years - 100years
Treatment Percutaneous coronary intervention
Clinical Study IdentifierNCT04475380
SponsorFoundation of Cardiovascular Research and Education Enschede
Last Modified on16 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

>18 years
requiring PCI and treated with Xience Sierra
capable of providing informed consent

Exclusion Criteria

known intolerance to components of the study DES or antithrombotic/anticoagulant therapy
planned elective surgery necessitating interruption of dual antiplatelet therapy (DAPT) < 3 months
patient is known to be pregnant, unlikely to adhere to follow-up or expected live < 1 year
Clear my responses

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.